A COMPARATIVE REVIEW OF THE ADVERSE-EFFECTS OF TREATMENTS FOR HYPERLIPEMIA

被引:38
作者
STEINER, A
WEISSER, B
VETTER, W
机构
[1] Department of Internal Medicine, Universitätsspital Zürich, Zürich, CH-8091
关键词
D O I
10.2165/00002018-199106020-00003
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Various lipid-lowering drugs have been shown to reduce serum cholesterol and serum triglycerides effectively. In view of trials indicating that lipid-lowering drugs may reduce cardiac morbidity and mortality but not the overall mortality in the study group, increased attention must be focused on potential harmful side effects during treatment with these agents. The adverse effects of many of the principal drugs in this category are discussed. Gastrointestinal symptoms, usually self-limited and reversible, are the most common side effects. Potential harmful adverse effects include drug interactions (cholestyramine), myopathy and hepatic injury (HMG-CoA reductase inhibitors), and increased gallstone formation and ventricular arrhythmias (clofibrate). Not all lipid-lowering drugs have been studied adequately on a long term basis, so that medications given for an indefinite period must be reevaluated frequently. However, there are several agents that lower serum lipid levels effectively and that have been used for more than 20 years without serious side effects.
引用
收藏
页码:118 / 130
页数:13
相关论文
共 114 条
[71]  
Levy R.I., Morganroth J., Rifkirid B.M., Treatment of hyperlipidemia, New England Journal of Medicine, 290, pp. 1295-1301, (1974)
[72]  
Lewis J.E., Long-term use of gemfibrozil (Lopid® in the treatment of dyslipidemia, Angiology, 33, pp. 603-612, (1982)
[73]  
Lindenbaum J., Maultiz R.M., Butler V.P., Inhibition of digoxin absorption by neomycin, Gastroenterology, 71, pp. 399-404, (1976)
[74]  
The Lipid Research Clinics coronary primary prevention trial results, Journal of the American Medical Association, 251, pp. 351-354, (1984)
[75]  
Mabuchi H., Sakai T., Sakai Y., Reduction of serum cholesterol in heterozygous patients with familial hypercholesterolemia: additive effects of compactin and cholestyramine, New England Journal of Medicine, 308, pp. 609-613, (1983)
[76]  
Manninen V., Malkonen M., Eisalo A., Virtamo J., Tuomiletho J., Et al., Gemfibrozil in the treatment of dyslipidaemia: a 5-year follow-up study, Acta Medica Scandinavica, 668, pp. 82-87, (1982)
[77]  
McCaughan D., Nine years of treatment with probucol, Artery, 10, pp. 56-70, (1982)
[78]  
Drug information, (1986)
[79]  
McGarvey J.F.X., Premature contractions and clofibrate. Correspondence, Journal of the American Medical Association, 225, (1974)
[80]  
Mellies M.J., Gartside P.S., Glatfelter L., Vink P., Guy, Et al., Effects of probucol on plasma cholesterol, high and low density lipoprotein cholesterol, and apolipoproteins A1 and A2 in adults with primary familial hypercholesterolemia, Metabolism, 29, pp. 956-963, (1980)